MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma (OS) is a primary bone cancer with poor prognosis, especially upon recurrence or chemoresistance.
• MicroRNAs (miRNAs) are key regulators of gene expression implicated in various cancers, including OS.
• miR-221 is frequently upregulated in OS tissues and cell lines, suggesting a role in tumorigenesis.

Purpose of the Study:

• To investigate the role of miR-221 in OS cell behavior, including invasion, migration, proliferation, and chemoresistance.
• To identify the direct molecular targets of miR-221 in OS.
• To explore the therapeutic potential of targeting miR-221 for overcoming cisplatin resistance in OS.

Main Methods:

• Quantitative real-time PCR to assess miR-221 expression.
• Cellular assays to evaluate invasion, migration, and proliferation.
• Cisplatin sensitivity assays (IC50 determination) in OS cells with miR-221 overexpression or inhibition.
• Luciferase reporter assays and Western blotting to confirm direct targeting of PPP2R2A by miR-221.
• Rescue experiments by restoring PPP2R2A expression in miR-221-overexpressing cells.

Main Results:

• miR-221 overexpression significantly enhanced OS cell invasion, migration, and proliferation.
• Overexpression of miR-221 conferred resistance to cisplatin, increasing IC50 values in MG-63 and SaoS-2 cells.
• miR-221 was confirmed to directly target the 3'-UTR of PPP2R2A mRNA.
• Restoration of PPP2R2A expression reversed the cisplatin resistance induced by miR-221 overexpression.

Conclusions:

• miR-221 plays a crucial role in promoting osteosarcoma progression and chemoresistance.
• The miR-221/PPP2R2A axis is a key mechanism driving cisplatin resistance in OS.
• Inhibition of miR-221 represents a promising therapeutic strategy to enhance chemosensitivity in osteosarcoma.